Abstract
Background
von Hippel–Lindau (VHL) disease is a hereditary cancer syndrome caused by germline mutations in the VHL gene. To date, more than 500 VHL families have been reported worldwide. However, few information is available about VHL germline mutations in mainland Chinese families.
Objective
To provide some preliminary information about the germline VHL mutations in mainland Chinese population.
Methods
A total of 27 index patients suspected of having VHL disease from unrelated Chinese families were studied by using direct DNA sequencing analysis and universal primer quantitative fluorescent multiplex polymerase chain reaction.
Results
The VHL germline mutations were detected in 26 (96%) probands. A total of 20 intragenic mutations (77%) were identified consisting of 12 missenses, 5 nonsenses, 2 micro-deletions and 1 novel intron mutation (IVS1-38C>T). Six large deletions (23%) were detected including four partial deletions and two complete deletions. Furthermore, a C>T substitution at nucleotide 470 (Pro86Leu) was observed in two unrelated Chinese families. Of note, two mutations (Asn78Ser and Ser80Ile) previously characterized as VHL type I mutations in Western VHL were associated with the type II Chinese family. In addition, a VHL germline mutation was also identified in a proband who did not fulfill the clinical diagnostic criteria for VHL disease.
Conclusions
The spectrum of VHL germline mutations in mainland Chinese population is similar to that observed in Western population, and Genetic testing can be powerful in diagnosis and clinical management of VHL disease.
Similar content being viewed by others
References
Ashida S, Furihata M, Tanimura M, Suqita O, Yamashita M, Miura T, Moriyama M, Shuin T (2003) Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: potential biomarkers for early diagnosis and postoperative metastatic status. J Urol 169:2089–2093
Ashida S, Okoda H, Chikazawa M, Tanimura M, Suqita O, Yamamoto Y, Nakamura S, Moriyama M, Shuin T (2000) Detection of circulating cancer cells with von Hippel–Lindau gene mutation in peripheral blood of patients with renal cell carcinoma. Clin Cancer Res 6:3817–3822
Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, Cohen D, Maher ER, Stanley AJ, Harnden P, Joyce A, Knowles M, Selby P (2006) Genetic and epigenetic analysis of von Hippel–Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 66:2000–2011
Catapano D, Muscarella LA, Guarnieri V, Zelante L, D’Angelo VA, D’Agruma L (2005) Hemangioblastomas of central nervous system: molecular genetic analysis and clinical management. Neurosurgery 56:1215–1221
Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G, Green J, Hsia YE, Lamiell J, Li H, Wei MH, Schmidt L, Tory K, Kuzmin I, Stackhouse T, Latif F, Linehan WM, Lerman M, Zbar B (1995) Germline mutations in the von Hippel–Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5:66–75
Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B (1995) von Hippel–Lindau disease: genetic, clinical, and imaging features. Radiology 194:629–642
Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER (2001) Contrasting effects on HIF–1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel–Lindau disease. Hum Mol Genet 10:1029–1038
Cybulski C, Krzystolik K, Murgia A, Górski B, Debniak T, Jakubowska A, Martella M, Kurzawski G, Prost M, Kojder I, Limon J, Nowacki P, Sagan L, Białas B, Kałuza J, Zdunek M, Omulecka A, Jaskólski D, Kostyk E, Koraszewska-Matuszewska B, Haus O, Janiszewska H, Pecold K, Starzycka M, Słomski R, Cwirko M, Sikorski A, Gliniewicz B, Cyryłowski L, Fiszer-Maliszewska Ł, Gronwald J, Tołoczko-Grabarek A, Zajaczek S, Lubiński J (2002) Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL gene. J Med Genet 39:E38
Gallou C, Chauveau D, Richard S, Joly D, Giraud S, Olschwang S, Martin N, Saquet C, Chretien Y, Mejean A, Correas JM, Benoit G, Colombeau P, Grunfeld JP, Junien C, Beroud C (2004) Genotype–phenotype correlation in von Hippel–Lindau families with renal lesions. Hum Mutat 24:215–224
Her C, Wu X, Griswold MD, Zhou F (2003) Human MutS homologue MSH4 physically interacts with von Hippel–Lindau tumor suppressor-binding protein 1. Cancer Res 63:865–872
Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W (2003) Regulation of microtubule stability by the von Hippel–Lindau tumour suppressor protein pVHL. Nat Cell Biol 5:64–70
Hes FJ, McKee S, Taphoorn MJB, Rehal P, van der Luijt RB, McMahon R, van der Smagt JJ, Dow D, Zewald RA, Whittaker J, Lips CJM, MacDonald F, Pearson PL, Maher ER (2000) Cryptic von Hippel–Lindau disease: germline mutations in haemangioblastoma only patients. J Med Genet 37:939–943
Hes FJ, van der Luijt RB, Janssen ALW, Zewald RA, de Jong GJ, Lenders JW, Links TP, Luyten GPM, Sijmons RH, Eussen HJ, Halley DJJ, Lips CJM, Pearson PL, van den Ouweland AMW, Majoor-Krakauer DF (2007) Frequency of Von Hippel–Lindau germline mutations in classic and non-classic Von Hippel–Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation-dependent probe amplification. Clin Genet 72:122–129
Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG Jr (2001) von Hippel–Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10:1019–1027
Iliopoulos O, Kibel A, Gray S, KaelinWG Jr (1995) Tumour suppression by the human von Hippel–Lindau gene product. Nat Med 1:822–826
Kaelin WG (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2:673–682
Kim WY, Kaelin WG (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22:4991–5004
Kuehn EW, Walz G, Benzing T (2007) Von Hippel–Lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development. Cancer Res 67:4537–4540
Kurban G, Duplan E, Ramlal N, Hudon V, Sado Y, Ninomiya Y, Pause A (2008) Collagen matrix assembly is driven by the interaction of von Hippel–Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2. Oncogene 27:1004–1012
Latif F, Tory K, Gnarra J, Yao M, Duh F-M, Orcutt ML, Kuzmin I, Stackhouse T, Modi W, Geil L, Schmidt L, Zhou F, Li H, Wei MH, Chen F, Glenn G, Choyke P, Walther MM, Weng Y, Duan DR, Dean M, Glavac D, Richards FM, Crossey PA, Ferguson-Smith MA, Le Paslier D, Chumakov I, Cohen D, Chinault CA, Maher ER, Zbar B, Linehan WM, Lerman MI (1993) Identification of the von Hippel–Lindau disease tumor suppressor gene. Science 260:1317–1320
Li L, Zhang L, Zhang X, Yan Q, Minamishima YA, Olumi AF, Mao M, Bartz S, Kaelin WG Jr (2007) Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol 27:5381–5392
Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G (2003) The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity. EMBO J 22:1857–1867
Lutz MS, Burk RD (2006) Primary cilium formation requires von Hippel–Lindau gene function in renal-derived cells. Cancer Res 66:6903–6907
Maher ER (2004) von Hippel–Lindau Disease. Curr Mol Med 4:833–842
Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT, Ferguson-Smith MA (1990) Clinical features and natural history of von Hippel–Lindau disease. Q J Med 77:1151–1163
Na X, Duan HO, Messing EM, Schoen SR, Ryan CK, di Sant’Agnese PA, Golemis EA, Wu G (2003) Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel–Lindau protein. EMBO J 22:4249–4259
Neumann HP, Bender BU, Berger DP, Laubenberger J, Schultze-Seemann W, Wetterauer U, Ferstl FJ, Herbst EW, Schwarzkopf G, Hes FJ, Lips CJ, Lamiell JM, Masek O, Riegler P, Mueller B, Glavac D, Brauch H (1998) Prevalence, morphology and biology of renal cell carcinoma in von Hippel–Lindau disease compared to sporadic renal cell carcinoma. J Urol 160:1248–1254
Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG, Iliopoulos O, Kaelin WG (1998) The von Hippel–Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1:959–968
Ong KR, Woodward ER, Killick P, Lim C, Macdonald F, Maher ER (2007) Genotype–phenotype correlations in von Hippel–Lindau Disease. Hum Mutat 28:143–149
Schoenfeld A, Davidowitz EJ, Burk RD (1998) A second major native von Hippel–Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci USA 95:8817–8822
Smits KM, Schouten LJ, van Dijk BA, Hulsbergen-van de Kaa CA, Wouters KA, Oosterwijk E, van Engeland M, van den Brandt PA (2008) Genetic and epigenetic alterations in the von Hippel–Lindau gene: the influence on renal cancer prognosis. Clin Cancer Res 14:782–787
Tong AL, Zeng ZP, Li HZ, Yang D, Lu L, Li M, Zhou YR, Zhang J, Chen S, Liang W (2006) von Hippel–Lindau gene mutation in non-syndromic familial pheochromocy-tomas. Ann N Y Acad Sci 1073:203–207
Woodward ER, Wall K, Forsyth J, Macdonald F, Maher ER (2007) VHL mutation analysis in patients with isolated central nervous system haemangioblastoma. Brain 130:836–842
Yoshida M, Ashida S, Kondo K, Kobayashi K, Kanno H, Shinohara N, Shitara N, Kishida T, Kawakami S, Baba M, Yamamoto I, Hosaka M, Shuin T, Yao M (2000) Germ-line mutation analysis in patients with von Hippel–Lindau disease in Japan: an extended study of 77 families. Jpn J Cancer Res 91:204–212
Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, Crossey PA, Webster AR, Affara NA, Ferguson-Smith MA, Brauch H, Glavac D, Neumann HP, Tisherman S, Mulvihill JJ, Gross DJ, Shuin T, Whaley J, Seizinger B, Kley N, Olschwang S, Boisson C, Richard S, Lips CH, Lerman M (1996) Germline mutations in the Von Hippel–Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 8:348–357
Acknowledgments
We are indebted to all the patients and their family members who participated in this study. We would like to thank many clinician at the different hospitals who provide blood samples and clinical information about their patients available in China: Dr. GP Zhou (Nanyang First Hospital), Dr. PY Xu (Hangzhou Fist Hospital), Dr. JY Niu (Qingzhou People Hospital), Dr. H Shi(Lianyungang First People Hospital), Dr. J Wang (Guizhou Province People Hospital). This research was supported in part by National Natural Science Foundation of China (No. 30571861) and Doctoral Foundation of Medical School of Shanghai Jiaotong University (No. BXJ0615).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, J., Huang, Y., Pan, J. et al. Germline mutations in the von Hippel–Lindau disease (VHL) gene in mainland Chinese families. J Cancer Res Clin Oncol 134, 1211–1218 (2008). https://doi.org/10.1007/s00432-008-0399-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-008-0399-x